Rochi Pharmaceutical PROTAC drug discovery technology summarizes the current popular target protein ligands; has established libraries for high-affinity targeting protein small molecule (TPSM) and small molecular fragments, libraries for high-affinity ubiquitin ligase small molecule (E3SM) and small molecular fragments, and linker systems that include diversified bi-functional linkers (BF-Linker). Those compound libraries help to quickly and efficiently synthesize a large number of high-activity PTROTAC bi-specific small molecules, thus greatly accelerating the process of drug R&D. Rochi will make every effort to establish and complete its PROTAC biological screening and testing platform, and the follow-up  development of preclinical stages，until the drug launch.

Rochi Pharmaceutical can provide comprehensive support and services for the safety and effectiveness evaluation of various new drugs and vaccines， specifically the research of LNP-mRNA drugs and vaccines, accumulating rich experience. Hence we establish the bioanalysis platform for mRNA vaccines.

Heterogeneous catalysts harboring transition metals can finely tune reaction selectivity and accelerate reaction rates. They also feature the great advantages of easy separation and reusability, boosting the efficiency and greenness of chemical process.

At Rochi Pharma, continuous flow chemistry has been routinely applied to projects. In addition to the development molecules from clients, Rochi has a number of building blocks that have been synthesized and scaled up via flow technology.

The application of continuous flow process in hydrogenation with micro-packed bed reactor is a viable and promising option to overcome the barriers of conventional batch reactors. At Rochi Pharma, micro-packed bed has been successfully used in different chemistries, including but not limited to:

Solid state chemistry research is an essential part of the new drug development process and can reduce the time to filing an IND application. It is also a key patent tool for new pharmaceutical companies to protect their product profit cycle.

In addition to the laboratory-level crystallization process development capabilities, Rochi Pharma is also equipped with commercialization, engineering, and equipment design capabilities. Services that can be provided include but are not limited to:

The engineering technology team brings together professionals with backgrounds in engineering, equipment, design, and process simulation. With the team's years of experience in commercial production management, plant equipment management, chemical process simulation expertise, and pharmaceutical design institutes, Rochi Pharma is able to carry out engineering design for different reaction processes, equipment requirements

Provide one-stop drug discovery services to new pharmaceutical companies

Provides CRDMO services for new drug development from discovery to commercial, meeting any material requirement at any scale and covering all categories for all synthetic molecular modalities, including small molecules, oligonucleotides, peptides and complex conjugates.

Has abundant of experience in molecular biology, cell biology, in vitro biology, institutional biology and other biological fields, and cooperates with a variety of biotechnology and professional scientific research teams.

Providing a comprehensive range of services in clinical development. We provide Phase I to Phase IV clinical research development services and Bioequivalence (BE) studies for products including pharmaceuticals, biologics, and medical devices

A Contract Testing, Development and Manufacturing Organization (CTDMO) that offers integrated platforms to transform the discovery, development, testing, manufacturing, and commercialization of cell and gene therapies. Our services and solutions accelerate time to market and support customer programs around the world.